ArticleOncology letters2026
KLF2 as a prognostic and potential therapeutic target associated with ferroptosis in serous ovarian cancer: An integrative bioinformatics and clinical validation study.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serous ovarian cancer (SOC), a prevalent histological subtype of ovarian cancer, poses a notable global threat to women's health. Ferroptosis has emerged as a pivotal focus in cancer research, presenting a promising novel therapeutic target. The present study aimed to identify key ferroptosis-related genes in SOC and evaluate their clinical implications. Gene expression profiles for SOC were obtained from the Gene Expression Omnibus database. Differential expression analysis and weighted gene co-expression network analysis, in conjunction with ferroptosis-related datasets, identified 22 differentially expressed genes associated with both SOC and ferroptosis. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses indicated their involvement in critical biological processes and pathways. Protein-protein interaction (PPI) network analysis identified four central hub genes: Kruppel-like factor 2 (KLF2), fatty acid binding protein 4 (FABP4), caveolin 1 (CAV1) and α-synuclein (SNCA). Validation using The Cancer Genome Atlas (TCGA) database confirmed significant downregulation of these genes in SOC (P<0.05), with an assessment of their potential diagnostic value. Peripheral blood samples were collected from 20 patients with SOC (experimental group) and 20 healthy volunteers (control group). Reverse transcription-quantitative PCR demonstrated that KLF2 was significantly downregulated in patients with SOC (P<0.05), while FABP4, CAV1 and SNCA did not show significant differences. Consequently, subsequent experiments concentrated on KLF2. The downregulation of KLF2 was further validated using the Human Protein Atlas database. Kaplan-Meier survival analysis revealed that low KLF2 expression was associated with a poor prognosis in patients with SOC. A nomogram suggested that KLF2 could serve as a prognostic biomarker for SOC. Immune infiltration analysis was performed based on TCGA data. Finally, interaction networks for microRNA-KLF2, transcription factor-KLF2 and chemical-KLF2 were constructed to predict potential molecular mechanisms and therapeutic drugs targeting KLF2 in SOC. These findings indicate that KLF2 may serve as a prognostic and potential therapeutic target related to ferroptosis in serous ovarian cancer, warranting further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.